Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017-A German Longitudinal Study Based on Claims Data.
Germany
claims data
medication prescriptions
morbidity expansion
type 2 diabetes
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
03 03 2023
03 03 2023
Historique:
received:
23
01
2023
revised:
27
02
2023
accepted:
28
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
With an attempt to understand possible mechanisms behind the severity-dependent development of type 2 diabetes (T2D) comorbidities, this study examines the trends of antidiabetic and cardiovascular diseases (CVD) medication prescriptions in individuals with T2D. The study is based on claims data from a statutory health insurance provider in Lower Saxony, Germany. The period prevalence of antidiabetic and CVD medication prescriptions was examined for the periods 2005-2007, 2010-2012, and 2015-2017 in 240,241, 295,868, and 308,134 individuals with T2D, respectively. (Ordered) logistic regression analyses were applied to examine the effect of time period on the number and prevalence of prescribed medications. Analyses were stratified by gender and three age groups. The number of prescribed medications per person has increased significantly for all examined subgroups. For the two younger age groups, insulin prescriptions decreased but those of non-insulin medications increased, while both increased significantly over time for the age group of 65+ years. Except for glycosides and antiarrhythmic medications, the predicted probabilities for CVD medications increased over the examined periods, with lipid-lowering agents demonstrating the highest increase. Results point towards an increase in medication prescriptions in T2D, which is in line with the evidence of the increase in most comorbidities indicating morbidity expansion. The increase in CVD medication prescriptions, especially lipid-lowering agents, could explain the specific development of severe and less severe T2D comorbidities observed in this population.
Sections du résumé
BACKGROUND
With an attempt to understand possible mechanisms behind the severity-dependent development of type 2 diabetes (T2D) comorbidities, this study examines the trends of antidiabetic and cardiovascular diseases (CVD) medication prescriptions in individuals with T2D.
METHODS
The study is based on claims data from a statutory health insurance provider in Lower Saxony, Germany. The period prevalence of antidiabetic and CVD medication prescriptions was examined for the periods 2005-2007, 2010-2012, and 2015-2017 in 240,241, 295,868, and 308,134 individuals with T2D, respectively. (Ordered) logistic regression analyses were applied to examine the effect of time period on the number and prevalence of prescribed medications. Analyses were stratified by gender and three age groups.
RESULTS
The number of prescribed medications per person has increased significantly for all examined subgroups. For the two younger age groups, insulin prescriptions decreased but those of non-insulin medications increased, while both increased significantly over time for the age group of 65+ years. Except for glycosides and antiarrhythmic medications, the predicted probabilities for CVD medications increased over the examined periods, with lipid-lowering agents demonstrating the highest increase.
CONCLUSIONS
Results point towards an increase in medication prescriptions in T2D, which is in line with the evidence of the increase in most comorbidities indicating morbidity expansion. The increase in CVD medication prescriptions, especially lipid-lowering agents, could explain the specific development of severe and less severe T2D comorbidities observed in this population.
Identifiants
pubmed: 36901500
pii: ijerph20054491
doi: 10.3390/ijerph20054491
pmc: PMC10001865
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Hypolipidemic Agents
0
Lipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The Ministry of Science and Culture of Lower Saxony
ID : 76202-19-1/18 (74ZN1810)
Références
BMJ Open. 2017 Jan 16;7(1):e013142
pubmed: 28093432
Diabetes Metab Syndr Obes. 2016 Nov 01;9:371-380
pubmed: 27843332
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Popul Health Metr. 2017 Feb 13;15(1):5
pubmed: 28193279
Front Vet Sci. 2017 Nov 10;4:193
pubmed: 29177157
J Aging Health. 2021 Mar;33(3-4):205-216
pubmed: 33135530
Can J Cardiol. 2018 May;34(5):552-564
pubmed: 29731019
Vnitr Lek. 2015 Feb;61(2):147-50
pubmed: 25813259
Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):412-21
pubmed: 17252613
JAMA. 2017 Mar 7;317(9):912-924
pubmed: 28267855
Prim Care Diabetes. 2013 Oct;7(3):229-33
pubmed: 23608219
J Am Med Dir Assoc. 2021 Sep;22(9):1898-1905.e1
pubmed: 34087226
Int J Epidemiol. 2014 Jun;43(3):962-70
pubmed: 24603316
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Mar;56(3):447-54
pubmed: 23334292
Eur J Clin Pharmacol. 2015 Dec;71(12):1415-27
pubmed: 26407687
Diabetes Metab Res Rev. 2011 May;27(4):383-91
pubmed: 21308948
Br J Clin Pharmacol. 2021 Jul;87(7):2807-2817
pubmed: 33269485
Dtsch Arztebl Int. 2016 Oct 21;113(42):712-719
pubmed: 27866566
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
J Gen Intern Med. 2020 May;35(5):1427-1434
pubmed: 31898135
Diabetes Care. 2007 Apr;30(4):848-53
pubmed: 17392545
Diabetol Metab Syndr. 2017 May 18;9:37
pubmed: 28529546
Sci Rep. 2021 May 27;11(1):11149
pubmed: 34045564
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
PLoS One. 2016 Oct 17;11(10):e0164704
pubmed: 27749939
Tunis Med. 2020 Feb;98(2):150-155
pubmed: 32395805
Dtsch Arztebl Int. 2014 Jun 27;111(26):453-63
pubmed: 25019922
Diabetes Metab Syndr Obes. 2020 Aug 25;13:3059-3068
pubmed: 32922056
Metabolism. 2021 Oct;123:154838
pubmed: 34333002